Sign in
Not yet recruitingPhase 2

Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome

Key facts

Who runs it
Sinfatin S.L
Where
Spain4 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
6 Nov 2026
Expected to end
Mar 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Rimonabant
  • Placebo
Record updated
12 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • Age between 18 and 75 years (both inclusive)
  • Have had COVID-19 at least 3 months before joining the study
  • Have been diagnosed with active PCS (Long COVID)
  • Have ongoing problems with memory or concentration due to long-COVID syndrome
  • Show signs of cognitive impairment in study assessments
  • Be willing to complete study assessments
  • Be able to understand and speak Spanish
  • Provide written consent to participate

Who cannot take part

  • Use substances or medications that may affect memory or concentration
  • Have an active or recent COVID-19 infection
  • Have severe mental health conditions, a pprevious suicide attempt
  • Have neurological conditions that may affect memory or concentration
  • Have other medical conditions that could explain their symptoms
  • Have severe lung, heart, liver, kidney, or bone disease
  • Have a known allergy to rimonabant
  • Have a high risk of suicide
  • Have a body mass index (BMI) greater than 40 kg/m²
  • Are unable to walk or attend study visits
  • Are taking medicines that may interact with the study treatment
  • Have taken part in another clinical trial within the last month
  • Are pregnant or breastfeeding
  • Are able to become pregnant or father a child and are not using effective contraception

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Post-COVID-19 syndrome

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main goal of the study is to assess the effect of rimonabant in cognitive performance in patients with Post-COVID-19 Syndrome, also known as long COVID.

Read full original descriptionShow less

The study will include 80 adults aged 18 to 75 years that will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.

The study will also help to learn about the safety of rimonabant.

The 2 groups in the trial

  • Rimonabant 5 mgTreatment being tested

    Participants receive rimonabant 5 mg orally once daily for 90 days.

    Treatment: Rimonabant

  • PlaceboPlacebo, for comparison

    Participants receive matching placebo orally once daily for 90 days.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients With Post-COVID-19 Syndrome (RIMOCOVID-1)
Criteria questions
Built from NCT07930637, who can take part
Record updated
12 November 2026